NovaBios-埃博拉病毒抗体快速检测卡

美国NovaBios埃博拉病毒抗体快速检测卡

广州健仑生物科技有限公司

本司长期供应埃博拉病毒检测试剂盒，其主要品牌包括美国NovaBios、广州创仑等CDC使用的进口产品，试剂盒的实验方法包括胶体金方法、ELISA方法、PCR方法等。

欢迎咨询

欢迎咨询2042552662

埃博拉病毒IgM、IgG、ELISA检测试剂、埃博拉快速检测试剂盒、

埃博拉病毒核酸检测试剂盒（荧光探针PCR）

西非工作、旅游埃博拉检测试剂盒

美国CDC使用的埃博拉诊断试剂——美国的NovaBios

美国NovaBios 埃博拉病毒抗体快速检测卡

【埃博拉简介】

埃博拉（Ebola virus）又译作伊波拉病毒。是一种十分罕见的病毒，1976年在苏丹南部和刚果（金）（旧称扎伊尔）的埃博拉河地区发现它的存在后，引起医学界的广泛关注和重视，“埃博拉”由此而得名。是一个用来称呼一群属于纤维病毒科埃博拉病毒属下数种病毒的通用术语。是一种能引起人类和灵长类动物产生埃博拉出血热的烈性传染病病毒，有很高的死亡率，在50%至90%之间，致死原因主要为中风、心肌梗塞、低血容量休克或多发性器官衰竭。

埃博拉出血热（EBHF）是由一种丝状病毒感染导致的急性出血性、动物源性传染病。1976年，埃博拉出血热在非洲的苏丹和扎伊尔暴发，病死率高达50% ～ 90% 。因该病始发于扎伊尔北部的埃博拉河流，并在该区域严重流行，故命名为埃博拉病毒，其形态学、致病性等与马尔堡病毒相似，但免疫原性有所区别。

【产品介绍】

该产品是世界卫生组织（WHO）*个批准用于埃博拉病毒检测的诊断试剂卡。不需要借助其他实验仪器设备，只需要采取几滴血清、血浆、血液样品，既可以检测，并在15分钟内就可以得知结果是否感染埃博拉病毒。该产品具有灵敏度高、操作方便、实验时间短等特点。

美国NovaBios 埃博拉病毒抗体快速检测卡

世界卫生组织12月23日宣布，由加拿大公共研发的疫苗可实现高效防护埃博拉病毒，迎来首种可预防埃博拉出血热的疫苗。
这项临床试验由世卫组织，几内亚卫生部等机构参与。相关研究报告已发表在新一期英国医学期刊《柳叶刀》上。
试验去年在几内亚开展，当时该地区仍不断出现新增埃博拉出血热病例。近1.2万直接或间接接触过埃博拉出血热患者的人参与了这项试验。
报告称，研究人员首先选取了18岁以上的成年人开展试验，这些人都不是孕妇、哺乳期妇女或重病患者。2119人立即接受了疫苗接种，2041人则推迟了21天接种疫苗。结果显示，立即接种疫苗的人都得到了有效防护，没有患上埃博拉出血热。但在推迟21天接种疫苗的人中，则有16人患上埃博拉出血热。
上述试验结果证实有效性后，研究人员将接种范围扩大至6岁以上的儿童，共有1677人立即接种了疫苗，其中包括194名儿童。结果显示，他们也得到了有效防护，没有患上埃博拉出血热。
在接种疫苗的5837人中，约一半的人出现了头痛、疲劳和肌肉酸痛等轻微的不良反应，个别人不良反应较重，但他们的身体都在数天内恢复了，并没有产生长期影响。在一直没有接种疫苗的人中，共有7人患上了埃博拉出血热。
生产疫苗的美国默沙东公司已经获得美国和欧盟方面的一些资格认证，这有利于相关监管机构加快审核这种新疫苗，使其尽快投入应用。
埃博拉病毒于1976年*发现，此后非洲多次报告偶发性疫情。2013年年底，埃博拉病毒在几内亚开始蔓延，随后扩散到周边的西非国家利比里亚、塞拉利昂，导致疫情加剧，1.1万余人死亡。直到今年3月，世卫组织才宣布西非埃博拉疫情已不构成“关注的突发公共卫生事件”。
本次研究报告的作者、世卫组织助理总干事玛丽－波勒·基尼说，尽管这项成果来得有点晚，许多人已经在西非埃博拉疫情中失去生命，但这至少能保证下一次埃博拉疫情来袭时，人们不会束手无策。
据英国广播公司(BBC)30日报道，利比里亚政府已经宣布将关闭全国的学校，阻止埃博拉病毒蔓延。

美国NovaBios 埃博拉病毒抗体快速检测卡

我司还提供其它进口或国产试剂盒：登革热、疟疾、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

想了解更多的NovaBios产品及服务请扫描下方二维码：

【公司名称】 广州健仑生物科技有限公司
【市场部】    杨永汉

【】 
【腾讯  】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室

The World Health Organization (WHO) announced on December 23 that the vaccine developed by the Canadian Public Health Agency would be effective in protecting Ebola virus and the first vaccine to prevent Ebola haemorrhagic fever.
This clinical trial is led by WHO, and the Ministry of Health of Guinea. The relevant research report has been published in the new issue of the British medical journal "Lancet".
The trial was carried out in Guinea last year, when new cases of Ebola haemorrhagic fever continued. Nearly 12,000 people who were directly or indirectly exposed to Ebola haemorrhagic fever were involved in the trial.
The report said the researchers first selected adults over the age of 18 to carry out trials, these people are not pregnant women, breast-feeding women or seriously ill patients. 2119 people immediay received vaccination, 2041 people were postponed 21 days vaccination. The results showed that people who were vaccinated immediay had been effectively protected against Ebola haemorrhagic fever. But in the postponed 21 days of vaccination, there are 16 people suffering from Ebola haemorrhagic fever.
After confirming the validity of the above test results, the researchers extended the vaccination to children over 6 years of age, and 1677 were vaccinated immediay, including 194 children. The results show that they have also been effectively protected against Ebola haemorrhagic fever.
Approximay half of the 5837 people who had been vaccinated had mild adverse reactions such as headache, fatigue and muscle soreness. Individuals were more adversely affected, but their bodies recovered within days and did not produce long-term effects. In the case of people who have not been vaccinated, a total of seven people suffering from Ebola haemorrhagic fever.
US Merck has produced a number of US and EU certification, which is conducive to the relevant regulatory agencies to speed up the review of this new vaccine, so that it is put into use as soon as possible.
Ebola virus was first discovered in 1976, after which Africa has repeatedly reported sporadic outbreaks. At the end of 2013, the Ebola virus began to spread in Guinea, then spread to the surrounding West African countries of Liberia, Sierra Leone, causing the epidemic to intensify, 1.1 million people died. It was not until March that WHO declared that the Ebola epidemic in West Africa did not constitute a "public health event of international concern".
"Although the results have come a bit late, many people have lost their lives in the Ebola epidemic in West Africa, but at least it will guarantee the next time," said Mary Paul Polly Gini, the assistant director of the study and the WHO Assistant Director-General. When the Bora epidemic struck, people would not be helpless.
According to the British Broadcasting Corporation (BBC) reported on the 30th, the Liberian government has announced that it will close the country's schools to prevent the spread of Ebola virus.